Second Primary Malignant Neoplasms in Survivors of Retinoblastoma in a
Single Ocular Oncology Practice
Abstract
Background: To describe the clinical features and course of a series of
survivors of retinoblastoma who developed a non-pineoblastoma second
primary malignant neoplasm (SPMN). Methods: A retrospective review of
patients treated for retinoblastoma who developed a SPMN was performed.
The demographics, clinical features and treatments for retinoblastoma,
pathologic types of SPMN, the intervals between the retinoblastoma
diagnosis and treatment and diagnosis of non-pineoblastoma SPMN,
treatment provided for the SPMN, and the survival outcomes of the
patients were evaluated. Results: Of 550 patients treated initially for
retinoblastoma, this series used the 15 (2.7%) that developed a
non-pineoblastoma SPMN, 14 of which (93.3%) had been treated for
bilateral retinoblastoma. All patients in this series had germline
retinoblastoma. The median time from retinoblastoma diagnosis to SPMN
diagnosis was 19.0 years (extremes 3.4 and 39.4 years). Six of the
fifteen patients died during the follow-up of their SPMN. Nine patients
were still alive without active residual SPMN at the last follow-up. The
median interval between initial retinoblastoma diagnosis and death in
the 6 patients who died of their SPMN was 18.8 years (extremes 6.2 and
34.6 years) and between diagnosis of the SPMN and death was 1.2 years
(extremes 0.25 and 4 years). Conclusion: A SPMN occurred in this series
in 2.7% of retinoblastoma survivors, and all occurred in patients with
germline retinoblastoma. All patients with SPMN who had been treated by
EBRT developed the SPMN in the field of prior radiation.